YmAbs Therapeutics (YMAB)
(Real Time Quote from BATS)
$14.86 USD
-0.43 (-2.81%)
Updated Apr 25, 2024 03:53 PM ET
After-Market: $14.83 -0.03 (-0.20%) 4:10 PM ET
1-Strong Buy of 5 1
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
YMAB 14.86 -0.43(-2.81%)
Will YMAB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for YMAB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for YMAB
New Strong Buy Stocks for April 19th
New Strong Buy Stocks for April 17th
YMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
Other News for YMAB
Y-mAbs to Present at 2024 ASCO Annual Meeting
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
Y-Mabs Therapeutics CFO Resigns, Ensures Smooth Transition
Y-mAbs Therapeutics says CFO Kruse will resign from his role
Y-mAbs Therapeutics CFO Bo Kruse resigns